Reliable blood biomarkers for Alzheimer’s disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson’s disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r= –0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.
JackCR, AlbertMS, KnopmanDS, McKhannGM, SperlingRA, CarrilloMC, ThiesB, PhelpsCH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 257–262.
2.
SkillbackT, FarahmandBY, RosenC, MattssonN, NaggaK, KilanderL, ReligaD, WimoA, WinbladB, SchottJM, BlennowK, EriksdotterM, ZetterbergH (2015) Cerebrospinal fluid tau and amyloid-ß1-42 in patients with dementia. Brain138, 2716–2731.
3.
RoherAE, EshCL, KokjohnTA, CastanoEM, Van VickleGD, KalbackWM, PattonRL, LuehrsDC, DaugsID, KuoY-M, EmmerlingMR, SoaresH, QuinnJF, KayeJ, ConnorDJ, SilverbergNB, AdlerCH, SewardJD, BeachTG, SabbaghMN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement5, 18–29.
4.
JanelidzeS, StomrudE, PalmqvistS, ZetterbergH, van WestenD, JerominA, SongL, HanlonD, Tan HehirCA, BakerD, BlennowK, HanssonO (2016) Plasma ß-amyloid in Alzheimer’s disease and vascular disease. Sci Rep6, 26801.
5.
MattssonN, ZetterbergH, JanelidzeS, InselPS, AndreassonU, StomrudE, PalmqvistS, BakerD, Tan HehirCA, JerominA, HanlonD, SongL, ShawLM, TrojanowskiJQ, WeinerMW, HanssonO, BlennowK (2016) Plasma tau in Alzheimer disease. Neurology87, 1827–1835.
6.
MattssonN, AndreassonU, ZetterbergH, BlennowK, Alzheimer’s Disease Neuroimaging Initiative (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol74, 557–566.
7.
NabersA, OlleschJ, SchartnerJ, KottingC, GeniusJ, HafermannH, KlafkiH, GerwertK, WiltfangJ (2016) Amyloid-ß-secondary structure distribution in cerebrospinal fluid and blood measured by an immuno-infrared-sensor: A biomarker candidate for Alzheimer’s disease. Anal Chem88, 2755–2762.
MuramoriF, KobayashiK, NakamuraI (1998) A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer’s disease, normal controls and non-Alzheimer neuropsychiatric diseases. Psychiatry Clin Neurosci52, 593–599.
10.
JesseS, SteinackerP, CepekL, ArnimCV, TumaniH, LehnertS, KretzschmarHA, BaierM, OttoM (2009) Glial fibrillary acidic protein and protein S-100B: Different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer’s disease and Creutzfeldt-Jakob disease. J Alzheimers Dis17, 541–551.
11.
FukuyamaR, IzumotoT, FushikiS (2001) The cere-brospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer’s disease patients and correlates with severity of dementia. Eur Neurol46, 35–38.
12.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
McKeithIG, DicksonDW, LoweJ, EmreM, O'BrienJT, FeldmanH, CummingsJ, DudaJE, LippaC, PerryEK, AarslandD, AraiH, BallardCG, BoeveB, BurnDJ, CostaD, Del SerT, DuboisB, GalaskoD, GauthierS, GoetzCG, Gomez-TortosaE, HallidayG, HansenLA, HardyJ, IwatsuboT, KalariaRN, KauferD, KennyRA, KorczynA, KosakaK, LeeVMY, LeesA, LitvanI, LondosE, LopezOL, MinoshimaS, MizunoY, MolinaJA, Mukaetova-LadinskaEB, PasquierF, PerryRH, SchulzJB, TrojanowskiJQ, YamadaM (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology65, 1863–1872.
16.
HughesAJ, DanielSE, KilfordL, LeesAJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry55, 181–184.
17.
MayerCA, BrunkhorstR, NiessnerM, PfeilschifterW, SteinmetzH, FoerchC (2013) Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases. PLoS One8, e62101.
18.
TanakaJ, MurakoshiK, TakedaM, KatoY, TadaK, HariguchiS, NishimuraT (1988) A high level of anti-GFAP autoantibody in the serum of patients with Alzheimer’s disease. Biomed Res9, 209–216.
19.
GarwoodCJ, RatcliffeLE, SimpsonJE, HeathPR, IncePG, WhartonSB (2017) Review: Astrocytes in Alzheimer’s disease and other age-associated dementias: A supporting player with a central role. Neuropathol Appl Neurobiol43, 281–298.
20.
JellingerKA, AttemsJ (2008) Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm115, 473–482.
21.
KamphuisW, MiddeldorpJ, KooijmanL, SluijsJA, KooiE-J, MoetonM, FreriksM, MizeeMR, HolEM (2014) Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging35, 492–510.
22.
LewczukP, RiedererP, O'BryantSE, VerbeekMM, DuboisB, VisserPJ, JellingerKA, EngelborghsS, RamirezA, ParnettiL, JackCR, TeunissenCE, HampelH, LleoA, JessenF, GlodzikL, de LeonMJ, FaganAM, MolinuevoJL, JansenWJ, WinbladB, ShawLM, AndreassonU, OttoM, MollenhauerB, WiltfangJ, TurnerMR, ZerrI, HandelsR, ThompsonAG, JohanssonG, ErmannN, TrojanowskiJQ, KaracaI, WagnerH, OecklP, van Waalwijk van DoornL, BjerkeM, KapogiannisD, KuiperijHB, FarottiL, LiY, GordonBA, EpelbaumS, VosSJB, KlijnCJM, Van Nos-trandWE, MinguillonC, SchmitzM, GalloC, Lopez MatoA, ThibautF, ListaS, AlcoleaD, ZetterbergH, BlennowK, KornhuberJ, Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry19, 244–328.
